ArriVent BioPharma, Inc. (AVBP) is a clinical-stage biopharmaceutical company focused on oncology, and it is a stock rather than an exchange-traded fund. Its analyst coverage shifted dramatically in October 2026, when the Phase 3 FURVENT trial of lead drug candidate firmonertinib failed to meet its primary endpoint of progression-free survival in first-line EGFR exon 20 insertion-mutated non-small cell lung cancer.
Across 11 recent, attributable targets, the range runs from $15 (LifeSci Capital) to $45 (Leerink Partners), with a mean of roughly $25.55, which rounds to the $26 central target used here. Because the $45 Leerink target predates the October data readout, the remaining 10 post-revision targets average closer to $24. Targets in the most recent cycle include $27 from H.C. Wainwright, $21 from Truist, $29 from BTIG, $25 from Oppenheimer, $30 from Guggenheim, $20 from Citi, $29 from B. Riley Securities, $22 from JonesTrading, and $18 from Jefferies.
The ratings remain Buy or Strong Buy across the board, but the price targets reflect reduced conviction in the lead program. Jefferies, for example, lowered its estimate of the probability of success for exon 20 in the U.S. and EU to 25% and 15%, respectively, from 75% and 55%. The wide $15-to-$45 spread shows genuine disagreement about how much value the remaining pipeline and balance sheet justify.
With AVBP near $14.16 and a 52-week range of $11.36 to $35.83, reaching $26 would require a gain of about 84% — a very large move by any standard. Before the October setback the shares traded around $28, so $26 would essentially mean recovering most of the ground lost in the selloff.
The path would depend on restoring confidence in the pipeline. ArriVent reported some secondary-endpoint benefits and no new safety signals in FURVENT, and the molecule firmonertinib is already approved and commercialized in China by its partner Allist. If the company can reposition firmonertinib in other EGFR settings or advance its antibody-drug conjugate (ADC) programs, such as ARR-217, the valuation debate could shift. In the near term, however, the stock trades below both its 50-day and 200-day moving averages, reflecting a damaged technical profile.
The stock is in a clear downtrend, trading near $14 versus a 52-week high of $35.83. The October capitulation low near $12 acts as near-term support, while the pre-crash consolidation and psychological levels around $15 to $18 represent initial resistance. The 50-day moving average near $22.73 and the 200-day moving average near $26.67 sit far above the current price, meaning a sustained move toward the target would require reclaiming multiple overhead levels.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms do not always state this explicitly and the October revisions show how quickly targets can shift. Investors should watch the next quarterly earnings release and guidance, any updated firmonertinib development strategy, progress on the ADC pipeline, analyst target revisions, financing activity, and the outcome of the securities investigations. No specific timing can be assigned to reaching any target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot shifting trends more efficiently than manual screening alone. For investors tracking volatile names like AVBP, automated signal tools can help put daily price action and changing momentum into context.
The $26 central target is the mean of 11 verified analyst targets, and it sits far above the current price near $14.16, implying roughly 84% upside. Support comes from a strong cash position, secondary clinical signals, and a diversified pipeline, while the failed Phase 3 FURVENT endpoint, litigation, dilution risk, and bearish technical structure are the principal obstacles. The $15-to-$45 target range reflects substantial disagreement about the company's residual value, so the target should be read as a statistical midpoint rather than a forecast. Whether AVBP approaches $26 will depend on evidence that the pipeline can generate value beyond the lead program's setback.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, AVBP has been loosely correlated with SYRE. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if AVBP jumps, then SYRE could also see price increases.
| Ticker / NAME | Correlation To AVBP | 1D Price Change % | ||
|---|---|---|---|---|
| AVBP | 100% | -0.46% | ||
| SYRE - AVBP | 40% Loosely correlated | +1.06% | ||
| REPL - AVBP | 37% Loosely correlated | -0.41% | ||
| RZLT - AVBP | 37% Loosely correlated | -5.56% | ||
| PRME - AVBP | 36% Loosely correlated | +9.77% | ||
| CRBU - AVBP | 35% Loosely correlated | -4.81% | ||
More | ||||